An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aura Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, has announced participation in two upcoming investor conferences. The first is Cowen's Virtual 3rd Annual Oncology Innovation Summit on June 2, 2022, featuring a fireside chat at 9:00 a.m. ET. The second is the Jefferies Global Healthcare Conference on June 8, 2022, with a presentation at 1:30 p.m. ET. Live webcasts for these events will be available on the company's website, with replays archived for 90 days. Aura is developing virus-like drug conjugates for various oncology indications, currently focusing on AU-011 for ocular cancers.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will participate in the following upcoming investor conferences:
Cowen’s Virtual 3rd Annual Oncology Innovation Summit on Thursday, June 2, 2022. Fireside chat at 9:00 a.m. ET.
Jefferies Global Healthcare Conference at the New York Marriot Marquis on Wednesday, June 8, 2022. Presentation at 1:30 p.m. ET.
A live webcast of the Cowen fireside chat and Jefferies presentation will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is currently in development for ocular cancers, with an ongoing Phase 2 dose escalation clinical trial evaluating first-line treatment of choroidal melanoma, a vision- and life-threatening form of eye cancer where standard of care with radiotherapy leaves patients with severe comorbidities, including major vision loss. Aura plans to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases. In addition, leveraging Aura’s technology platform, Aura is developing AU-011 more broadly across multiple cancers, starting with a planned Phase 1 clinical trial in patients with non-muscle invasive bladder cancer. Aura is headquartered in Cambridge, MA.
For more information, visit aurabiosciences.com, or follow us on Twitter and LinkedIn.
Investor and Media Contact:
Matthew DeYoung Argot Partners 212-600-1902 | aura@argotpartners.com
Source: Aura Biosciences Inc.
FAQ
What are the dates and times for Aura Biosciences' upcoming investor conferences?
Aura Biosciences will participate in Cowen's Virtual 3rd Annual Oncology Innovation Summit on June 2, 2022, at 9:00 a.m. ET and the Jefferies Global Healthcare Conference on June 8, 2022, at 1:30 p.m. ET.
Where can I watch the live webcasts of Aura Biosciences' investor presentations?
The live webcasts of Aura Biosciences' investor presentations will be available on the 'Investors & Media' page of their website under 'Events & Presentations.'
What is AU-011 and its significance for Aura Biosciences?
AU-011, developed by Aura Biosciences, is a virus-like drug conjugate targeting ocular cancers, specifically in a Phase 2 trial for choroidal melanoma. It aims to destroy cancer cells and stimulate long-lasting immune responses.
What ongoing clinical trials is Aura Biosciences conducting?
Aura Biosciences is conducting a Phase 2 dose escalation clinical trial for its lead candidate AU-011 in treating choroidal melanoma and plans a Phase 1 trial for non-muscle invasive bladder cancer.
